Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Allon Therapeutics · Progressive Supranuclear Palsy
Phase 2 / Phase 3
Completed
313
2013-01
Industry sponsor intelligence
Allon TherapeuticsClinical Pipeline.
Lead-sponsor view of Allon Therapeutics's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 3
- Recruiting
- 0
- Active
- 0
- Completed
- 3
- Results posted
- 0
- Avg enrollment
- 230
Pipeline overview
Programs by phase and activity.
Velocity
Allon Therapeutics trials by start year
Study start year · indexed snapshot
Development
Trials by phase
4phase labels
Early Phase 10
Phase 10
Phase 23
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Davunetide → | 3 | 0 | 3 | 1 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery
Allon Therapeutics · Mild Cognitive Impairment
Phase 2
Completed
234
2012-10
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
Allon Therapeutics · Mild Cognitive Impairment, So Stated
Phase 2
Completed
144
2012-10
Search sponsor records
All Allon Therapeutics studies.
This page groups studies where Allon Therapeutics is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
3 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT01110720Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyJan 17, 2013NCT00404014Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft SurgeryOct 24, 2012NCT00422981Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive ImpairmentOct 24, 2012